Influence on the Health of the Partner Affected by Tumor Disease in the Wife or Husband Based on a Population-Based Register Study of Cancer in Sweden

2009 ◽  
Vol 27 (28) ◽  
pp. 4781-4786 ◽  
Author(s):  
Katarina Sjövall ◽  
Bo Attner ◽  
Thor Lithman ◽  
Dennis Noreen ◽  
Barbro Gunnars ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Health Care ◽  
Cancer Patients ◽  
Health Care Costs ◽  
Cancer Diagnosis ◽  
Health Care Use ◽  
Psychiatric Diagnoses ◽  
Male Partners ◽  
Costs Of Care ◽  
Care Costs

Purpose To examine health care use and health care costs among partners of persons with cancer. Patients and Methods Partners of patients with colon, rectal, lung, breast, and prostate cancer (N = 11,076) were identified via linked data from the Tumor Registry of Southern Sweden and Census Registry of Sweden. Health care use, total costs of health care, and diagnosis of the partner were studied before and after diagnosis of the cancer patient. Results Health care use for partners increased in terms of in-patient care after the cancer diagnosis. A significant increase was seen the second year for partners of patients with colon cancer (risk ratio [RR], 1.55; 95% CI, 1.28 to 1.87) and lung cancer (RR, 1.50; 95% CI, 1.26 to 1.79). Psychiatric diagnoses increased after the cancer diagnosis in the total sample, with a significant increase for partners of colon (RR, 2.66; 95% CI, 1.71 to 4.22), lung (RR, 3.16; 95% CI, 2.23 to 4.57), and prostate cancer patients (RR, 1.68; 95% CI, 1.32 to 2.15). Costs of care increased more than the consumer price index the two years after the cancer diagnosis. Costs of care increased most for male partners and especially for younger male partners (age 25 to 64 years) of patients with colon, rectal, and lung cancers. Conclusion The results showed increased health care costs and an increase in psychiatric diagnoses after the cancer diagnosis among partners of cancer patients. Further research is needed to learn more about the situation of the partner and to identify persons at risk of psychiatric morbidity. Knowledge is also needed on how to support the partner in the most efficient way.

scholarly journals PD15-12 HEALTH CARE SPENDING IN HIGH RESOURCE PROSTATE CANCER PATIENTS: WHAT CONTRIBUTES MOST TO HIGH PROSTATE CANCER HEALTH CARE COSTS?

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Maxine Sun* ◽  
Maya Marchese ◽  
David Fallon Friedlander ◽  
Alexander Putnam Cole ◽  
Sean Anthony Fletcher ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Health Care ◽  
Cancer Patients ◽  
Health Care Costs ◽  
Health Care Spending ◽  
High Resource ◽  
Care Costs

scholarly journals Factors contributing to post-stroke health care utilization and costs. Secondary results from the Life After Stroke (LAST) study, a pragmatic randomized controlled trial

2020 ◽  
Author(s):  
Øystein Døhl ◽  
Vidar Halsteinli ◽  
Torun Askim ◽  
Mari Gunnes ◽  
Hege Ihle Hansen ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Costs ◽  
Gait Speed ◽  
Standard Care ◽  
Controlled Trial ◽  
Health Care Use ◽  
Post Stroke ◽  
Randomized Controlled ◽  
Care Costs

Abstract Background The result from the Life After Stroke (LAST) study showed that an 18-month follow up program as part of the primary health care, did not improve maintenance of motor function for stroke survivors. In this study we evaluated whether the follow-up program could lead to a reduction in the use of health care compared to standard care. Furthermore, we analyse to what extent differences in health care costs for stroke patients could be explained by individual need factors (such as physical disability, cognitive impairment, age, gender and marital status), and we tested whether a generic health related quality of life (HRQoL) is able to predict the utilisation of health care services for patients post-stroke as well as more disease specific indexes. Methods The Last study was a multicentre, pragmatic, single-blinded, randomized controlled trial. Adults (age ≥18 years) with first-ever or recurrent stroke, community dwelling, with modified Rankin Scale <5. The study included 380 persons recruited 10 to 16 weeks post-stroke, randomly assigned to individualized coaching for 18 months (n=186) or standard care (n=194). Individual need was measured by the Motor assessment scale (MAS), Barthel Index, Hospital Anxiety and Depression Scale (HADS), modified Rankin Scale (mRS) and Gait speed. HRQoL was measured by EQ-5D-5L. Health care costs were estimated for each person based on individual information of health care use. Multivariate regression analysis was used to analyse cost differences between the groups and the relationship between individual costs and determinants of health care utilisation. Results There were higher total costs in the intervention group. MAS, Gait speed, HADS and mRS were significant identifiers of costs post-stroke, as was EQ-5D-5L. Conclusion Long term, regular individualized coaching did not reduce health care costs compared to standard care. We found that MAS, Gait speed, HADS and mRS were significant predictors for future health care use. The generic EQ-5D-5L performed equally well as the more detailed battery of outcome measures, suggesting that HRQoL measures may be a simple and efficient way of identifying patients in need of health care after stroke and targeting groups for interventions. Clinical Trial Registration : https://www.clinicaltrials.gov NCT01467206.

Estimating health care costs for advanced metastatic bladder cancer patients who are lost to follow-up: Applications of the Kaplan-Meier sampling average (KMSA).

2017 ◽  
Vol 35 (8_suppl) ◽  
pp. 21-21
Author(s):  
Binglin Yue ◽  
Maria L. Lankford ◽  
Pamela Landsman-Blumberg
Keyword(s):  
Health Care ◽  
Bladder Cancer ◽  
Cancer Patients ◽  
Health Care Costs ◽  
Traditional Method ◽  
Total Cost ◽  
Metastatic Bladder Cancer ◽  
Lost To Follow Up ◽  
Care Costs

21 Background: There is an increasing need to evaluate the quality and cost of care within oncology. Estimating health care costs for patients who are lost to follow-up or censored often results in underestimating costs, biasing comparative assessments. This study compared traditional costing approaches with that of KMSA methods for patients treated for metastatic bladder cancer. Methods: Advanced metastatic bladder cancer patients receiving second line chemotherapy were identified from the Truven Health MarketScan Claims Databases (04/2011 to 09/2014). All-cause health care costs represent the total dollars paid to all providers of care regardless of diagnosis and were inflated to 2014 USD. Total, medical, pharmacy, and site-of-care costs from treatment initiation to death, end-of-enrollment, or end-of-study period were compared using the KMSA and traditional methods. In KMSA, the follow-up period is divided into small uniform intervals; total cost in each interval is then multiplied by the individual patient’s survival probability at the beginning of each interval and then summed across the intervals. Results: The censoring rate of patients’ follow-up was 49%. The mean per patient total health care captured by traditional method was only 72% of the total cost estimated by KMSA method or $32,930 less per patient. Overall, underestimates ranged from 28% to 41% with pharmacy, ER, and lab service costs underestimated the largest when using the traditional method. Conclusions: The KMSA produced estimates more reflective of actual patient-level health care costs in this claims-based observational cancer study compared to traditional methods by accounting for the effect of censoring. Researchers should consider KMSA when evaluating and comparing costs of care in the presence of variable follow-up.[Table: see text]

scholarly journals Health Care Costs Among Renal Cancer Patients Using Pazopanib and Sunitinib

2015 ◽  
Vol 21 (9) ◽  
pp. 841-843 ◽  
Author(s):  
Elizabeth A. MacLean ◽  
Rickard Sandin ◽  
Jack Mardekian
Keyword(s):  
Health Care ◽  
Cancer Patients ◽  
Health Care Costs ◽  
Renal Cancer ◽  
Care Costs

scholarly journals PCN112 Estimating Resources Utilization and Health Care Costs Related to Colorectal Cancer Patients in Saudi Arabia

2020 ◽  
Vol 23 ◽  
pp. S442-S443
Author(s):  
B. Balkhi ◽  
A. Alharbi ◽  
M. Al Najjar ◽  
A. Alghamdi ◽  
Y. AlRuthia ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Health Care ◽  
Saudi Arabia ◽  
Cancer Patients ◽  
Health Care Costs ◽  
Colorectal Cancer Patients ◽  
Care Costs
Sign in / Sign up

Export Citation Format

Share Document